Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bio-tam 2.0 is a multi-ingredient dietary supplement developed by Bio-Gen Innovations, specifically formulated for estrogen management and post-cycle therapy (PCT). It is marketed as a natural alternative to pharmaceutical selective estrogen receptor modulators (SERMs) like tamoxifen. The formulation contains a blend of botanical extracts and phytochemicals, including *Brassaiopsis glomerulata*, Diindolylmethane (DIM), Acacetin, and *Prunella vulgaris*. These components work synergistically to inhibit the aromatase enzyme (CYP19A1), which converts androgens into estrogens, and to modulate estrogen receptor activity. By reducing systemic estrogen levels and optimizing estrogen metabolism, Bio-tam 2.0 is intended to prevent estrogen-related side effects such as gynecomastia and excessive water retention in individuals undergoing hormonal fluctuations.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Bio-tam 2.0.